Evaluation of continuous infusion suramin in metastatic breast cancer: Impact on plasma levels of insulin-like growth factors (IGFs) and IGF- binding proteins

Clinical Cancer Research

Volumn 3, Issue 10, 1997, Pages 1713-1720

  Lawrence, James B ^a   Conover, Cheryl A ^a   Haddad, Tufia C ^a   Ingle, James N ^a   Reid, Joel M ^a   Ames, Matthew M ^a   Suman, Vera J ^a   Marks, Randolph S ^a   Erlichman, Charles ^a   Hartmann, Lynn C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; SURAMIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOAVAILABILITY; BREAST CANCER; BREAST METASTASIS; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; FEMALE; HORMONE RESPONSE; HUMAN; HUMAN CELL; IMMUNORADIOMETRIC ASSAY; MITOGENICITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; SOMATOMEDINS; SURAMIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0030879459     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Dickson, R. B., and Lippman, M. E. Growth factors in breast cancer. Endocr. Rev., 16: 559-589, 1995.
2. Daughaday, W. H. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology, 127: 1-4, 1990.
3. Lee, A. V., and Yee, D. Insulin-like growth factors and breast cancer. Biomed. Pharmacother., 49: 415-421, 1995.
4. LeRoith, D., Werner, H., Beitner-Johnson, D., and Roberts, C. T., Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev., 16: 143-163, 1995.
5. Peyrat, J. P., and Bonneterre, J. Type 1 IGF receptor in human breast diseases. Breast Cancer Res. Treat., 22: 59-67, 1992.
6. Neuenschwander, S., Roberts, C. T., Jr., and LeRoith, D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology, 136: 4298-4303, 1995.
7. Arteaga, C. L., and Osborne, C. K. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res., 49: 6237-6241, 1989.
8. Arteaga, C. L., Kitten, L. J., Coronado, E. B., Jacobs, S., Kull, F. C., Jr., Allred, D. C., and Osborne, C. K. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J. Clin. Invest., 84: 1418-1423, 1989.
9. Brunner, N., Yee, D., Kern, F. G., Spang-Thomsen, M., Lippman, M. E., and Cullen, K. Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II). Eur. J. Cancer, 29A: 562-569, 1993.
10. Coffey, R. J., Leof, E. B., Shipley, G. D., and Moses, H. L. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J. Cell. Physiol., 132: 143-148, 1987.
11. Vincent, T. S., Hazen-Martin, D. J., and Garvin, A. J. Inhibition of insulin like growth factor II autocrine growth of Wilms' tumor by suramin in vitro and in vivo. Cancer Lett., 103: 49-56, 1996.
12. Eisenberger, M. A., Sinibaldi, V. J., Reyno, L. M., Sridhara, R., Jodrell, D. I., Zuhowski, E. G., Tkaczuk, K. H., Lowit, M. H., Hemady, R. K., Jacobs. S. C., Van Echo, D., and Egorin, M. J. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J. Clin. Oncol., 13: 2174-2186, 1995.
13. Kobayashi, K., Vokes, E. E., Vogelzang, N. J., Janisch, L., Soliven, B., and Ratain, M. J. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J. Clin. Oncol., 13: 2196-2207, 1995.
14. Scher, H., and Kelly, W. K. Suramin: defining the role in the clinic. Princ. Pract. Oncol., 7: 1-16, 1993.
15. Vignon, F., Prebois, C., and Rochefort, H. Inhibition of breast cancer growth by suramin. J. Natl. Cancer Inst., 84: 38-42, 1992.
16. Miglietta, L., Barreca, A., Repetto, L., Costantini, M., Rosso, R., and Boccardo, F. Suramin and plasma insulin-like growth factor levels in metastatic cancer patients. Anticancer Res., 13: 2473-2476, 1993.
17. Pollock, M., Huynh, H., and Lefebvre, S. Tamoxifen reduces plasma insulin-like growth factor-I (IGF-I). Breast Cancer Res. Treat., 22: 91-100, 1992.
18. Colletti, R., Roberts, J., Devlin, J., and Copeland, K. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res., 49: 1882-1889, 1989.
19. Shimasaki, S., and Ling, N. Identification and molecular characterization of insulin-like growth factor-binding proteins. Prog. Growth Factor Res., 3: 243-266, 1991.
20. Oh, Y., Nagalla, S., Yamanaka, Y., Kim, H., and Wilson, E. Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. J. Biol. Chem., 271: 30322-30325, 1996.
21. Baxter, R. C. Insulin-like growth factor-binding proteins in the human circulation: a review. Horm. Res. (Basel), 42: 140-144, 1994.
22. Supko, J. G., and Malspeis, L. A. A rapid isocratic HPLC assay of suramin (NCS 34936) in human plasma. J. Liq. Chromatogr., 13: 727-741, 1990.
23. Conover, C. A., Kiefer, M. C., and Zapf, J. Posttranslational regulation of insulin-like growth factor (IGF)-binding protein 4 in normal and transformed human fibroblasts: IGF dependence and biological studies. J. Clin. Invest., 91: 1129-1137, 1993.
24. Lamson, G., Giudice, L. C., and Rosenfeld, R. G. A simple assay for proteolysis of IGFBP-3. J. Clin. Endocrinol. Metab., 72: 1391-1393, 1991.
25. Eisenberger, M. A., and Reyno, L. M. Suramin. Cancer Treat. Rev., 20: 259-273, 1994.
26. Lassarre, C., and Binoux, M. Insulin-like growth factor-binding protein 3 is functionally altered in pregnancy plasma. Endocrinology, 134: 1254-1262, 1994.
27. Karey, K., and Sirbaska, D. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17β-estradiol. Cancer Res., 48: 4083-4092, 1988.
28. Ketelslegers, J-M., Maiter, D., Maes, M., Underwood, L. E., and Thissen, J-P. Nutritional regulation of the growth hormone and insulin-like growth factor-binding proteins. Horm. Res. (Basel), 45: 252-257, 1996.
29. Prosser, C. G., and Schwander, J. Influence of insulin-like growth factor-binding protein 2 on plasma clearance and transfer of insulin-like growth factors I and II from plasma into mammary-derived lymph and milk of goats. J. Endocrinol., 150: 121-127, 1996.
30. Blat, C., Villaudy, J., and Binoux, M. In vivo proteolysis of plasma insulin-like growth factor (IGF)-binding protein 3 results in increased availability of IGF to target cells. J. Clin. Invest., 93: 2286-2290, 1994.
31. Bang, P., Stangenberg, M., Westgren, M., and Rosenfeld, R. Decreased ternary complex formation and predominance of a 29-kDa IGFBP-3 fragment in human fetal plasma. Growth Regul., 4: 68-76, 1994.
32. Ramirez, L. H., Julieron, M., Bonnay, M., Koscielny, S., Zhao, Z., Gouyette, A., and Munck, J-N. Stimulation of tumor growth in vitro and in vivo by suramin on the VX2 model. Invest. New Drugs, 13: 51-53, 1995.
33. Pommier, G., Garrouste, F., El Atiq, F., Roccabianca, M., Marvaldi, J., and Remacle-Bonnet, M. Potential autocrine role of insulin-like growth factor II during suramin-induced differentiation of HT29-D4 human colonic adenocarcinoma cell line. Cancer Res., 52: 3182-3188, 1992.
34. Lalou, C., Silve, C., Rosato, R., Segovia, B., and Bioux, M. Interactions between insulin-like growth factor I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein 3 production and proteolysis in human osteosarcoma cells. Enodcrinology, 135: 2318-2326, 1994.
35. Baxter, R., Holman, S., Corbould, A., Stranks, S., Ho, P., and Braund, W. Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia. J. Clin. Endocrinol. Metab., 80: 2700-2708, 1995.
36. Price, W., Stiles, A., Moats-Staats, B., and D'Erchole, J. Gene expression of insulin-like growth factors (IGFs), the type IIGF receptor, and IGF-binding proteins in dexamethasone-induced fetal growth retardation. Endocrinology, 130: 1424-1432, 1992.
37. Allen, D., and Goldberg, B. Stimulation of collagen synthesis and linear growth by growth hormone in glucocorticoid-treated children. Pediatrics, 89: 416-421, 1992.